Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.4507
52 Week Range 0.4401 - 24.9900
All the news: https://ir.jsyoule.com/news.html
Total Cash (mrq) 28.26M
Total Cash Per Share (mrq) 0.56
Total Debt (mrq) 6.8M
Book Value Per Share (mrq) 1.18
Jan 19, 2024 0.5000 0.5150 0.4401 0.4507 0.4507 422,292
Jan 15, 2024 0.5510 0.5600 0.4800 0.4900 0.4900 649,400
Jan 08, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 01, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 04, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300
Shares Outstanding 5 51.75M
Float 1.69M
$GDHG 20% short🔥 pic.twitter.com/VqaCaCVTB6
— Tiffiny Fawcett (@tiffinyfawcett) January 19, 2024
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.4507
52 Week Range 0.4401 - 24.9900
All the news: https://ir.jsyoule.com/news.html
Total Cash (mrq) 28.26M
Total Cash Per Share (mrq) 0.56
Total Debt (mrq) 6.8M
Book Value Per Share (mrq) 1.18
Jan 19, 2024 0.5000 0.5150 0.4401 0.4507 0.4507 422,292
Jan 15, 2024 0.5510 0.5600 0.4800 0.4900 0.4900 649,400
Jan 08, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 01, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 04, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300
Shares Outstanding 5 51.75M
Float 1.69M
$GDHG 20% short🔥 pic.twitter.com/VqaCaCVTB6
— Tiffiny Fawcett (@tiffinyfawcett) January 19, 2024
JAGUAR HEALTH (JAGX) 0,0969 (-0,0062) -6,01%
Time for a strong recovery
Jan 16, 2024 0.0979 0.1000 0.0856 0.0968 0.0968 13,063,913
Jan 12, 2024 0.1170 0.1260 0.1020 0.1030 0.1030 52,733,500
Jan 11, 2024 0.1160 0.1160 0.1050 0.1080 0.1080 5,687,300
Jan 10, 2024 0.1190 0.1200 0.1130 0.1150 0.1150 4,672,400
Jan 09, 2024 0.1300 0.1300 0.1170 0.1190 0.1190 6,548,300
Jan 08, 2024 0.1400 0.1400 0.1280 0.1290 0.1290 5,226,500
Jan 05, 2024 0.1480 0.1490 0.1400 0.1400 0.1400 2,720,300
Jan 04, 2024 0.1410 0.1520 0.1400 0.1500 0.1500 4,476,200
Jan 03, 2024 0.1510 0.1540 0.1310 0.1420 0.1420 4,005,900
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
JAGUAR HEALTH (JAGX) 0,0969 (-0,0062) -6,01%
Time for a strong recovery
Jan 16, 2024 0.0979 0.1000 0.0856 0.0968 0.0968 13,063,913
Jan 12, 2024 0.1170 0.1260 0.1020 0.1030 0.1030 52,733,500
Jan 11, 2024 0.1160 0.1160 0.1050 0.1080 0.1080 5,687,300
Jan 10, 2024 0.1190 0.1200 0.1130 0.1150 0.1150 4,672,400
Jan 09, 2024 0.1300 0.1300 0.1170 0.1190 0.1190 6,548,300
Jan 08, 2024 0.1400 0.1400 0.1280 0.1290 0.1290 5,226,500
Jan 05, 2024 0.1480 0.1490 0.1400 0.1400 0.1400 2,720,300
Jan 04, 2024 0.1410 0.1520 0.1400 0.1500 0.1500 4,476,200
Jan 03, 2024 0.1510 0.1540 0.1310 0.1420 0.1420 4,005,900
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
TAOP: 1.31 + 6.52%
52w: 1.11 - 10.20
SHENZHEN, China, Jan. 16, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported an 80% increase in the Company's contract revenue value for the full year of 2023, as compared with the full year of 2022. The Company entered into contracts totaling RMB 270 million (approximately US$37.94 million) during 2023, with the majority of the revenue expected to be recognized within fiscal year 2023 and the balance in fiscal year 2024.
Taoping achieved strong growth throughout 2023, with demand led by the Company's city partner ecosystem and comprehensive portfolio of core high-value, high-traffic area software development and advertising business solutions. The Company continued to invest in its impressive new product pipeline and R&D efforts into powerful new AI-driven solutions, which the Company expects will make significant contributions during fiscal year 2024.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "We are very encouraged with our strong growth in 2023 as our business rebounded along with the overall economy. As spending on travel and outdoor activities returned, we saw a significant uptick in interest in our solutions from customers. Based on customer demand levels, we expect continued strong growth in 2024, with increased contributions from Taoping's powerful new Cloud Nest AI system and intelligent Cloud platform, our leading-edge Smart City solutions and innovative off-grid wastewater treatment solution, as well as other AI-driven businesses."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
TAOP: 1.31 + 6.52%
52w: 1.11 - 10.20
SHENZHEN, China, Jan. 16, 2024 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported an 80% increase in the Company's contract revenue value for the full year of 2023, as compared with the full year of 2022. The Company entered into contracts totaling RMB 270 million (approximately US$37.94 million) during 2023, with the majority of the revenue expected to be recognized within fiscal year 2023 and the balance in fiscal year 2024.
Taoping achieved strong growth throughout 2023, with demand led by the Company's city partner ecosystem and comprehensive portfolio of core high-value, high-traffic area software development and advertising business solutions. The Company continued to invest in its impressive new product pipeline and R&D efforts into powerful new AI-driven solutions, which the Company expects will make significant contributions during fiscal year 2024.
Mr. Lin Jianghuai, Chairman and CEO of Taoping, said: "We are very encouraged with our strong growth in 2023 as our business rebounded along with the overall economy. As spending on travel and outdoor activities returned, we saw a significant uptick in interest in our solutions from customers. Based on customer demand levels, we expect continued strong growth in 2024, with increased contributions from Taoping's powerful new Cloud Nest AI system and intelligent Cloud platform, our leading-edge Smart City solutions and innovative off-grid wastewater treatment solution, as well as other AI-driven businesses."
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us on X.
Organovo Holdings, Inc. (ONVO): 1.0600-0.0300 (-2.75%)
52 Week Range 1.0000 - 3.4000
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.
The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
“We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman. “Our 3D human tissue models rely on primary cells isolated from individual donors with disease, and we believe our findings to constitute a translational research “gold standard” far superior and complimentary to preclinical animal models alone. FXR314 shows excellent results in standard preclinical models as well. In this presentation, data from our 3D models of IBD, especially the effect of FXR314 on multiple endpoints of IBD including epithelial barrier function and fibrosis in a wide set of Crohn’s disease and ulcerative colitis donors, will be shown.”
Organovo’s current development program for FXR314 focuses on inflammatory bowel disease, where the drug’s differentiated mechanism of action, as highlighted in Organovo’s recently provided mechanism of action video at http://organovo.com/about, provides substantial promise that the drug’s impact will strongly complement the biology of other successful drugs in ulcerative colitis and Crohn’s disease. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025. The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. For more information visit Organovo's website at www.organovo.com.
Jan 12, 2024 1.0700 1.0900 1.0501 1.0600 1.0600 38,173
Jan 01, 2024 1.1000 1.2700 1.0500 1.0600 1.0600 1,573,500
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Oct 31, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Sep 30, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Aug 31, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Jul 31, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jun 30, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
May 31, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
Apr 30, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Mar 31, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Oct 31, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Sep 30, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Aug 31, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Jul 31, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jun 30, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
May 31, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
Apr 30, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Mar 31, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Oct 31, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Sep 30, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Aug 31, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Jul 31, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jun 30, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
May 31, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
Apr 30, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Mar 31, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Organovo Holdings, Inc. (ONVO): 1.0600-0.0300 (-2.75%)
52 Week Range 1.0000 - 3.4000
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.
The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
“We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman. “Our 3D human tissue models rely on primary cells isolated from individual donors with disease, and we believe our findings to constitute a translational research “gold standard” far superior and complimentary to preclinical animal models alone. FXR314 shows excellent results in standard preclinical models as well. In this presentation, data from our 3D models of IBD, especially the effect of FXR314 on multiple endpoints of IBD including epithelial barrier function and fibrosis in a wide set of Crohn’s disease and ulcerative colitis donors, will be shown.”
Organovo’s current development program for FXR314 focuses on inflammatory bowel disease, where the drug’s differentiated mechanism of action, as highlighted in Organovo’s recently provided mechanism of action video at http://organovo.com/about, provides substantial promise that the drug’s impact will strongly complement the biology of other successful drugs in ulcerative colitis and Crohn’s disease. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025. The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. For more information visit Organovo's website at www.organovo.com.
Jan 12, 2024 1.0700 1.0900 1.0501 1.0600 1.0600 38,173
Jan 01, 2024 1.1000 1.2700 1.0500 1.0600 1.0600 1,573,500
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Oct 31, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Sep 30, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Aug 31, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Jul 31, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jun 30, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
May 31, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
Apr 30, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Mar 31, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Oct 31, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Sep 30, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Aug 31, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Jul 31, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jun 30, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
May 31, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
Apr 30, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Mar 31, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Oct 31, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Sep 30, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Aug 31, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Jul 31, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jun 30, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
May 31, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
Apr 30, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Mar 31, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
JAGX: pre-market : 0.1170 +0.0086 (+7.9336%)
Pre-Market Volume 20,699,953
Pre-Market High $0.1578 (08:09:42 AM)
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
JAGX: pre-market : 0.1170 +0.0086 (+7.9336%)
Pre-Market Volume 20,699,953
Pre-Market High $0.1578 (08:09:42 AM)
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
USEG: DEBT FREE
HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- U.S. Energy Corp. (Nasdaq: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the operation of high-quality producing oil and natural gas assets, today announced it had completed a series of non-core asset divestitures.
HIGHLIGHTS
All-cash proceeds of approximately $7.2 million;
Divested assets averaged approximately 200 barrels of oil equivalent per day (83% oil) from July-September 2023, or 12% of USEG total production over the same period;
All proceeds used to reduce existing debt, leaving USEG materially debt-free1;
No changes to the Company’s existing $20.0 million borrowing base;
Represents the majority of USEG’s non-operated assets.
MANAGEMENT COMMENTARY
“Throughout the fourth quarter, we executed on a series of asset divestitures representing the majority of U.S. Energy’s non-operated assets,” stated Ryan Smith, Chief Executive Officer of U.S. Energy Corp. “The assets divested represent legacy USEG properties, primarily in current non-core focus areas, and will allow the Company to realize immediate additional corporate overhead savings. With proceeds going directly towards debt reduction, U.S. Energy now sits in a position of increased liquidity across all measures and meaningful portions of our 2024 oil production hedged at an average price in the low $80’s. As we enter 2024, we look forward to focusing our capital allocation efforts on the Company’s highest rate of return growth initiatives, maintaining a strong balance sheet, and driving shareholder returns.”
BALANCE SHEET AND LIQUIDITY UPDATE
The below table provides an overview of U.S. Energy’s debt and cash balances, as well as the Company’s hedge position, at both September 30, 2023 and December 31, 2023.
HEDGING PROGRAM UPDATE
The following table reflects the hedged volumes under U.S. Energy’s commodity derivative contracts and the average fixed prices at which production is hedged for full year 2024, as of January 9, 2024:
ABOUT U.S. ENERGY
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. More information about U.S. Energy Corp. can be found at www.usnrg.com .
Net debt/net cash calculation arrived at by taking debt outstanding plus cash plus value of commodity derivative portfolio.
12/31/2023 hedge position valued as of January 9, 2024.
Liquidity calculated by taking the difference between the Company’s current $20.0 million borrowing base and the Company’s net debt/cash positions.
Time for a strong rebound?:
Jan 09, 2024 1.0700 1.0700 1.0200 1.0400 1.0400 38,135
Jan 01, 2024 1.0400 1.1200 1.0200 1.0600 1.0600 335,400
Dec 01, 2023 1.1700 1.1700 0.8300 1.0000 1.0000 2,016,000
Oct 31, 2023 1.4300 1.4700 1.1200 1.1700 1.1700 1,099,800
Sep 30, 2023 1.3400 1.5500 1.2300 1.4500 1.4500 1,788,400
Aug 31, 2023 1.3500 1.4500 1.3100 1.3500 1.3500 636,600
Jul 31, 2023 1.6300 1.7600 1.3100 1.3300 1.3300 1,051,100
Jun 30, 2023 1.4400 1.6500 1.3700 1.6000 1.6000 1,189,900
May 31, 2023 1.4500 1.6000 1.3500 1.4200 1.4200 1,248,500
May 18, 2023 0.023 Dividend
Apr 30, 2023 1.3700 1.4900 1.2800 1.4200 1.3954 1,447,000
Mar 31, 2023 2.1000 2.6900 1.2200 1.3800 1.3561 22,256,700
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7296 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1025 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.3653 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2387 1,400,000
Nov 07, 2022 0.023 Dividend
Oct 31, 2022 2.9500 3.0700 2.4900 2.6600 2.5688 1,529,500
Sep 30, 2022 3.0000 3.2300 2.7500 2.9800 2.8778 2,165,500
Aug 31, 2022 3.4000 3.9400 2.6700 2.9200 2.8198 3,529,400
Aug 05, 2022 0.023 Dividend
Jul 31, 2022 3.5000 4.2400 3.3000 3.4700 3.3281 4,419,700
Jun 30, 2022 3.4300 3.8400 3.2600 3.5300 3.3857 1,276,000
May 31, 2022 4.4100 5.2800 3.3700 3.4600 3.3185 8,493,600
Apr 30, 2022 3.8100 4.6500 3.6700 4.4400 4.2584 6,559,700
Apr 13, 2022 0.023 Dividend
Mar 31, 2022 4.3700 5.1900 3.7400 3.8500 3.6723 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.1493 86,797,700
USEG: DEBT FREE
HOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- U.S. Energy Corp. (Nasdaq: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the operation of high-quality producing oil and natural gas assets, today announced it had completed a series of non-core asset divestitures.
HIGHLIGHTS
All-cash proceeds of approximately $7.2 million;
Divested assets averaged approximately 200 barrels of oil equivalent per day (83% oil) from July-September 2023, or 12% of USEG total production over the same period;
All proceeds used to reduce existing debt, leaving USEG materially debt-free1;
No changes to the Company’s existing $20.0 million borrowing base;
Represents the majority of USEG’s non-operated assets.
MANAGEMENT COMMENTARY
“Throughout the fourth quarter, we executed on a series of asset divestitures representing the majority of U.S. Energy’s non-operated assets,” stated Ryan Smith, Chief Executive Officer of U.S. Energy Corp. “The assets divested represent legacy USEG properties, primarily in current non-core focus areas, and will allow the Company to realize immediate additional corporate overhead savings. With proceeds going directly towards debt reduction, U.S. Energy now sits in a position of increased liquidity across all measures and meaningful portions of our 2024 oil production hedged at an average price in the low $80’s. As we enter 2024, we look forward to focusing our capital allocation efforts on the Company’s highest rate of return growth initiatives, maintaining a strong balance sheet, and driving shareholder returns.”
BALANCE SHEET AND LIQUIDITY UPDATE
The below table provides an overview of U.S. Energy’s debt and cash balances, as well as the Company’s hedge position, at both September 30, 2023 and December 31, 2023.
HEDGING PROGRAM UPDATE
The following table reflects the hedged volumes under U.S. Energy’s commodity derivative contracts and the average fixed prices at which production is hedged for full year 2024, as of January 9, 2024:
ABOUT U.S. ENERGY
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. More information about U.S. Energy Corp. can be found at www.usnrg.com .
Net debt/net cash calculation arrived at by taking debt outstanding plus cash plus value of commodity derivative portfolio.
12/31/2023 hedge position valued as of January 9, 2024.
Liquidity calculated by taking the difference between the Company’s current $20.0 million borrowing base and the Company’s net debt/cash positions.
Time for a strong rebound?:
Jan 09, 2024 1.0700 1.0700 1.0200 1.0400 1.0400 38,135
Jan 01, 2024 1.0400 1.1200 1.0200 1.0600 1.0600 335,400
Dec 01, 2023 1.1700 1.1700 0.8300 1.0000 1.0000 2,016,000
Oct 31, 2023 1.4300 1.4700 1.1200 1.1700 1.1700 1,099,800
Sep 30, 2023 1.3400 1.5500 1.2300 1.4500 1.4500 1,788,400
Aug 31, 2023 1.3500 1.4500 1.3100 1.3500 1.3500 636,600
Jul 31, 2023 1.6300 1.7600 1.3100 1.3300 1.3300 1,051,100
Jun 30, 2023 1.4400 1.6500 1.3700 1.6000 1.6000 1,189,900
May 31, 2023 1.4500 1.6000 1.3500 1.4200 1.4200 1,248,500
May 18, 2023 0.023 Dividend
Apr 30, 2023 1.3700 1.4900 1.2800 1.4200 1.3954 1,447,000
Mar 31, 2023 2.1000 2.6900 1.2200 1.3800 1.3561 22,256,700
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7296 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1025 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.3653 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2387 1,400,000
Nov 07, 2022 0.023 Dividend
Oct 31, 2022 2.9500 3.0700 2.4900 2.6600 2.5688 1,529,500
Sep 30, 2022 3.0000 3.2300 2.7500 2.9800 2.8778 2,165,500
Aug 31, 2022 3.4000 3.9400 2.6700 2.9200 2.8198 3,529,400
Aug 05, 2022 0.023 Dividend
Jul 31, 2022 3.5000 4.2400 3.3000 3.4700 3.3281 4,419,700
Jun 30, 2022 3.4300 3.8400 3.2600 3.5300 3.3857 1,276,000
May 31, 2022 4.4100 5.2800 3.3700 3.4600 3.3185 8,493,600
Apr 30, 2022 3.8100 4.6500 3.6700 4.4400 4.2584 6,559,700
Apr 13, 2022 0.023 Dividend
Mar 31, 2022 4.3700 5.1900 3.7400 3.8500 3.6723 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.1493 86,797,700
Taoping Inc. (TAOP) : 1.2300-0.3200 (-20.6452%)
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
time for a strong rebound:
Jan 04, 2024 1.3700 1.4500 1.2200 1.2300 1.2300 286,207
Jan 03, 2024 1.9700 1.9700 1.4500 1.5500 1.5500 1,125,200
Jan 02, 2024 1.5200 2.0100 1.4200 1.8900 1.8900 4,050,700
Taoping Inc. (TAOP) : 1.2300-0.3200 (-20.6452%)
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
time for a strong rebound:
Jan 04, 2024 1.3700 1.4500 1.2200 1.2300 1.2300 286,207
Jan 03, 2024 1.9700 1.9700 1.4500 1.5500 1.5500 1,125,200
Jan 02, 2024 1.5200 2.0100 1.4200 1.8900 1.8900 4,050,700
JAGX: 0.1509 + 5.97%
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease – an ultrarare CDD – and short bowel syndrome (SBS) in the US, EU, and Middle East/North Africa regions, with results expected in 2024
SAN FRANCISCO, CA / January 4, 2024 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the United States Patent and Trademark Office on January 2, 2024 issued a new U.S. patent to Napo for methods for treating congenital diarrheal disorders (CDDs) in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug.
“We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core focus on CDD indications,” said Lisa Conte, Jaguar's founder, president, and CEO.
Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) – an ultrarare CDD – and short bowel syndrome (SBS) in the US, European Union, and Middle East/North Africa (MENA) regions, with results expected in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for MVID or SBS for these debilitating conditions.
MVID is a catastrophic medical situation for pediatric patients, and there are currently no approved drug treatments.
Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) from a few to up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the associated sequelae from diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, and other secondary symptoms, and these symptoms emerge either early or late, and many times become life-threatening.
Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency for both MVID and SBS with intestinal failure. The ODD programs in the US and EU qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.
As with all potential follow-on indications, Jaguar and Napo prioritize IP protection. Napo currently holds approximately 148 patents and approximately 50 patents pending. To date, crofelemer is the only oral plant-based prescription medicine approved under the FDA’s Botanical Guidance, which provides an important additional exclusivity advantage due to the inherent practicalities limiting the pathway by which a generic version of the drug could be produced.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that results of investigator-initiated and investigator IND proof-of-concept studies of crofelemer for MVID and SBS will be available in 2024, and Jaguar’s expectation that, in accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
JAGX: 0.1509 + 5.97%
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease – an ultrarare CDD – and short bowel syndrome (SBS) in the US, EU, and Middle East/North Africa regions, with results expected in 2024
SAN FRANCISCO, CA / January 4, 2024 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the United States Patent and Trademark Office on January 2, 2024 issued a new U.S. patent to Napo for methods for treating congenital diarrheal disorders (CDDs) in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug.
“We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core focus on CDD indications,” said Lisa Conte, Jaguar's founder, president, and CEO.
Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) – an ultrarare CDD – and short bowel syndrome (SBS) in the US, European Union, and Middle East/North Africa (MENA) regions, with results expected in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for MVID or SBS for these debilitating conditions.
MVID is a catastrophic medical situation for pediatric patients, and there are currently no approved drug treatments.
Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) from a few to up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the associated sequelae from diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, and other secondary symptoms, and these symptoms emerge either early or late, and many times become life-threatening.
Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency for both MVID and SBS with intestinal failure. The ODD programs in the US and EU qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.
As with all potential follow-on indications, Jaguar and Napo prioritize IP protection. Napo currently holds approximately 148 patents and approximately 50 patents pending. To date, crofelemer is the only oral plant-based prescription medicine approved under the FDA’s Botanical Guidance, which provides an important additional exclusivity advantage due to the inherent practicalities limiting the pathway by which a generic version of the drug could be produced.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that results of investigator-initiated and investigator IND proof-of-concept studies of crofelemer for MVID and SBS will be available in 2024, and Jaguar’s expectation that, in accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
Jaguar Health (jagx) : 0.1439 – 4.83%
Time for a strong recovery
https://www.sec.gov/Archives/edgar/data/1462830/000156761923007925/doc1.htm
Shares Outstanding 50.76M
Implied Shares Outstanding 50.76M
Float 40.68M
https://jaguar.health/pipeline/
Jan 03, 2024 0.1505 0.1538 0.1310 0.1439 0.1439 3,672,347
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Dec 28, 2023 0.1670 0.1680 0.1610 0.1620 0.1620 2,962,900
Dec 27, 2023 0.1720 0.1720 0.1590 0.1630 0.1630 3,800,700
Dec 26, 2023 0.1700 0.1750 0.1660 0.1720 0.1720 2,583,600
Dec 22, 2023 0.1550 0.1680 0.1540 0.1670 0.1670 4,743,000
Dec 21, 2023 0.1540 0.1550 0.1500 0.1530 0.1530 2,175,200
Dec 20, 2023 0.1560 0.1570 0.1460 0.1500 0.1500 4,123,200
Dec 19, 2023 0.1600 0.1680 0.1550 0.1620 0.1620 3,909,500
Dec 18, 2023 0.1650 0.1680 0.1500 0.1550 0.1550 4,216,500
Dec 15, 2023 0.1680 0.1900 0.1600 0.1600 0.1600 8,481,100
Dec 14, 2023 0.1550 0.1700 0.1540 0.1670 0.1670 4,522,300
Dec 13, 2023 0.1610 0.1610 0.1510 0.1530 0.1530 6,719,900
Dec 12, 2023 0.1880 0.1900 0.1680 0.1690 0.1690 4,945,700
Dec 11, 2023 0.2250 0.2290 0.1700 0.1830 0.1830 14,068,500
Dec 08, 2023 0.2890 0.2890 0.2650 0.2650 0.2650 2,691,000
Dec 07, 2023 0.3150 0.3190 0.2860 0.2880 0.2880 4,557,500
Dec 06, 2023 0.3240 0.3300 0.3160 0.3200 0.3200 3,074,500
Dec 05, 2023 0.3800 0.3800 0.3100 0.3240 0.3240 8,376,900
Dec 04, 2023 0.3500 0.4050 0.3420 0.3900 0.3900 9,457,200
Dec 01, 2023 0.3560 0.3600 0.3470 0.3560 0.3560 5,757,900
Nov 30, 2023 0.3570 0.3830 0.3470 0.3540 0.3540 2,080,300
Nov 29, 2023 0.3460 0.3700 0.3430 0.3500 0.3500 1,866,800
Nov 28, 2023 0.3300 0.3530 0.2910 0.3490 0.3490 2,643,600
Nov 27, 2023 0.3600 0.3600 0.3420 0.3500 0.3500 2,798,900
Nov 24, 2023 0.3500 0.3760 0.3410 0.3740 0.3740 2,158,200
Nov 22, 2023 0.3600 0.3670 0.3300 0.3430 0.3430 3,410,800
Nov 21, 2023 0.3740 0.4000 0.3390 0.3470 0.3470 11,863,800
Nov 20, 2023 0.4250 0.5140 0.4130 0.4620 0.4620 12,583,000
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
https://jaguar.health
Full Time Employees: 60
Jaguar Health (jagx) : 0.1439 – 4.83%
Time for a strong recovery
https://www.sec.gov/Archives/edgar/data/1462830/000156761923007925/doc1.htm
Shares Outstanding 50.76M
Implied Shares Outstanding 50.76M
Float 40.68M
https://jaguar.health/pipeline/
Jan 03, 2024 0.1505 0.1538 0.1310 0.1439 0.1439 3,672,347
Jan 02, 2024 0.1520 0.1560 0.1510 0.1510 0.1510 3,847,200
Dec 29, 2023 0.1640 0.1700 0.1500 0.1510 0.1510 4,813,700
Dec 28, 2023 0.1670 0.1680 0.1610 0.1620 0.1620 2,962,900
Dec 27, 2023 0.1720 0.1720 0.1590 0.1630 0.1630 3,800,700
Dec 26, 2023 0.1700 0.1750 0.1660 0.1720 0.1720 2,583,600
Dec 22, 2023 0.1550 0.1680 0.1540 0.1670 0.1670 4,743,000
Dec 21, 2023 0.1540 0.1550 0.1500 0.1530 0.1530 2,175,200
Dec 20, 2023 0.1560 0.1570 0.1460 0.1500 0.1500 4,123,200
Dec 19, 2023 0.1600 0.1680 0.1550 0.1620 0.1620 3,909,500
Dec 18, 2023 0.1650 0.1680 0.1500 0.1550 0.1550 4,216,500
Dec 15, 2023 0.1680 0.1900 0.1600 0.1600 0.1600 8,481,100
Dec 14, 2023 0.1550 0.1700 0.1540 0.1670 0.1670 4,522,300
Dec 13, 2023 0.1610 0.1610 0.1510 0.1530 0.1530 6,719,900
Dec 12, 2023 0.1880 0.1900 0.1680 0.1690 0.1690 4,945,700
Dec 11, 2023 0.2250 0.2290 0.1700 0.1830 0.1830 14,068,500
Dec 08, 2023 0.2890 0.2890 0.2650 0.2650 0.2650 2,691,000
Dec 07, 2023 0.3150 0.3190 0.2860 0.2880 0.2880 4,557,500
Dec 06, 2023 0.3240 0.3300 0.3160 0.3200 0.3200 3,074,500
Dec 05, 2023 0.3800 0.3800 0.3100 0.3240 0.3240 8,376,900
Dec 04, 2023 0.3500 0.4050 0.3420 0.3900 0.3900 9,457,200
Dec 01, 2023 0.3560 0.3600 0.3470 0.3560 0.3560 5,757,900
Nov 30, 2023 0.3570 0.3830 0.3470 0.3540 0.3540 2,080,300
Nov 29, 2023 0.3460 0.3700 0.3430 0.3500 0.3500 1,866,800
Nov 28, 2023 0.3300 0.3530 0.2910 0.3490 0.3490 2,643,600
Nov 27, 2023 0.3600 0.3600 0.3420 0.3500 0.3500 2,798,900
Nov 24, 2023 0.3500 0.3760 0.3410 0.3740 0.3740 2,158,200
Nov 22, 2023 0.3600 0.3670 0.3300 0.3430 0.3430 3,410,800
Nov 21, 2023 0.3740 0.4000 0.3390 0.3470 0.3470 11,863,800
Nov 20, 2023 0.4250 0.5140 0.4130 0.4620 0.4620 12,583,000
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
https://jaguar.health
Full Time Employees: 60
TAOP: 1,45 +6,62%
volume: 1.844.643
intraday high: 1.76 + 0.395 (+28,93%)
52w high: 10.20
Time for a strong rebound!!
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
A lot of new big contracts:
Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd.
Nov. 8, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB15 million contract to provide integrated, cloud-based data analytics services to Shenzhen Chuangzhi Tiancheng Tech Co Ltd.
Oct. 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB10 million contract to provide cloud-based advertising services to Shenzhen Zhaoyou Tech Co. Ltd.
Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
TAOP: 1,45 +6,62%
volume: 1.844.643
intraday high: 1.76 + 0.395 (+28,93%)
52w high: 10.20
Time for a strong rebound!!
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
A lot of new big contracts:
Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd.
Nov. 8, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB15 million contract to provide integrated, cloud-based data analytics services to Shenzhen Chuangzhi Tiancheng Tech Co Ltd.
Oct. 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB10 million contract to provide cloud-based advertising services to Shenzhen Zhaoyou Tech Co. Ltd.
Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
TAOP: 1.76 + 0.395 (+28,93%)
52w high: 10.20
Time for a strong rebound!!
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
A lot of new big contracts:
Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd.
Nov. 8, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB15 million contract to provide integrated, cloud-based data analytics services to Shenzhen Chuangzhi Tiancheng Tech Co Ltd.
Oct. 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB10 million contract to provide cloud-based advertising services to Shenzhen Zhaoyou Tech Co. Ltd.
Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
TAOP: 1.76 + 0.395 (+28,93%)
52w high: 10.20
Time for a strong rebound!!
Shares Outstanding 1.97M
Implied Shares Outstanding 1.97M
Float 1.33M
Book Value Per Share (mrq) 5.13
A lot of new big contracts:
Dec. 11, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB16.2 million contract to provide AI servers to Fuzhou Shenpeng Technology Co. Ltd.
Nov. 8, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB15 million contract to provide integrated, cloud-based data analytics services to Shenzhen Chuangzhi Tiancheng Tech Co Ltd.
Oct. 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today announced the Company was awarded a RMB10 million contract to provide cloud-based advertising services to Shenzhen Zhaoyou Tech Co. Ltd.
Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company entered into contracts totaling RMB 191 million (approximately US$26.55 million) during the first nine months of 2023, the revenues from which the Company expects to recognize within fiscal year 2023.
U.S. ENERGY (USEG) : 1.12
52w: 0.83 – 2.69
Buyback, dividend and maybe…
Shares Outstanding 25.51M
Implied Shares Outstanding 25.51M
Float 2.91M
U.S. Energy’s Board of Directors has decided to initiate a formal review process to evaluate strategic alternatives for the Company. The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders.
U.S. Energy Corp. (Nasdaq: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing assets, announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $5.0 million of its outstanding shares of common stock in the open market, in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934. The Company’s decision to repurchase its shares, as well as the timing of such repurchases, will depend on a variety of factors, including the ongoing assessment of the Company’s capital needs, the market price of the Company’s common stock, general market conditions and other corporate considerations, as determined by management. The repurchase program may be suspended or discontinued at any time.
May 18, 2023 0.023 Dividend
Feb 09, 2023 0.023 Dividend
Nov 07, 2022 0.023 Dividend
Aug 05, 2022 0.023 Dividend
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
U.S. ENERGY (USEG) : 1.12
52w: 0.83 – 2.69
Buyback, dividend and maybe…
Shares Outstanding 25.51M
Implied Shares Outstanding 25.51M
Float 2.91M
U.S. Energy’s Board of Directors has decided to initiate a formal review process to evaluate strategic alternatives for the Company. The Board of Directors and management team are committed to acting in the best interests of the Company, its stockholders and its stakeholders.
U.S. Energy Corp. (Nasdaq: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing assets, announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $5.0 million of its outstanding shares of common stock in the open market, in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934. The Company’s decision to repurchase its shares, as well as the timing of such repurchases, will depend on a variety of factors, including the ongoing assessment of the Company’s capital needs, the market price of the Company’s common stock, general market conditions and other corporate considerations, as determined by management. The repurchase program may be suspended or discontinued at any time.
May 18, 2023 0.023 Dividend
Feb 09, 2023 0.023 Dividend
Nov 07, 2022 0.023 Dividend
Aug 05, 2022 0.023 Dividend
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.78665 – 15.16%
$2 sounds good $GDHG https://t.co/UiEp1kyUJM
— Hamilton "Ham" Porter (It’s me I promise) (@HamiltonHamPor2) December 27, 2023
$GDHG looking for major bounce here. Could pull something crazy from these levels. https://t.co/ruUjIaqtjv
— Lowbudgettrader (@lowgamblez) December 27, 2023
$GDHG major squeeze ahead .. dropped from $25 I’m holding here .. run could be epic IMO 🏃♂️ current SP .94 cents 200%-500%+ run active ! $WLGS $MULN $MURA $CCCC $BETS strong momentum today
— professor D🔥man (@professorDman1) December 26, 2023
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.78665 – 15.16%
$2 sounds good $GDHG https://t.co/UiEp1kyUJM
— Hamilton "Ham" Porter (It’s me I promise) (@HamiltonHamPor2) December 27, 2023
$GDHG looking for major bounce here. Could pull something crazy from these levels. https://t.co/ruUjIaqtjv
— Lowbudgettrader (@lowgamblez) December 27, 2023
$GDHG major squeeze ahead .. dropped from $25 I’m holding here .. run could be epic IMO 🏃♂️ current SP .94 cents 200%-500%+ run active ! $WLGS $MULN $MURA $CCCC $BETS strong momentum today
— professor D🔥man (@professorDman1) December 26, 2023
HIGH RISK!!
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0,82-11,56%
all time low
Dec 27, 2023 1.0900 0.9201 0.8120 0.8200 0.8200 435,687
Dec 26, 2023 1.0900 1.1200 0.9000 0.9270 0.9270 2,768,800
Dec 22, 2023 1.1800 1.1800 1.0700 1.1400 1.1400 623,400
Dec 21, 2023 1.1600 1.2150 1.0800 1.2000 1.2000 606,100
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,133,200
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Golden Heaven Group Holdings Ltd., an offshore holding company, engages in the development, construction, management, and operation of urban amusement parks, water parks, amusement projects, and amusement facilities in China. It operates six amusement parks, water parks, and complementary recreational facilities. The company was incorporated in 2020 and is headquartered in Nanping, the People's Republic of China.
https://www.jsyoule.com/
Total Cash (mrq) 28.26M
Total Debt (mrq) 6.8M
Float 1.69M
Shares Short (Nov 29, 2023) 395.64k
ATUS: 2.7799 +0.0499 +1.8278%
52w high: 5.5700
Altice USA, Inc., together with its subsidiaries, provides broadband communications and video services in the United States, Canada, Puerto Rico, and the Virgin Islands. It offers broadband, video, telephony, and mobile services to residential and business customers. The company's video services include delivery of broadcast stations and cable networks; over the top services; video-on-demand, high-definition channels, digital video recorder, and pay-per-view services; and platforms for video programming through mobile applications. It also provides voice over Internet protocol telephone services; and mobile services, such as data, talk, and text. In addition, the company offers Ethernet, data transport, IP-based virtual private networks, Internet access, and telephony services; hosted telephony services, managed Wi-Fi, managed desktop and server backup, and collaboration services comprising audio and web conferencing; fiber-to-the-tower services to wireless carriers; data services consisting of wide area networking and dedicated data access, as well as wireless mesh networks; and enterprise class telephone services that include traditional multi-line phone service. Further, it provides business e-mail, hosted private branch exchange, web space storage, and network security monitoring; and international calling and toll free numbers. Additionally, the company offers audience-based and IP-authenticated cross-screen advertising solutions; and television and digital advertising services, as well as operates news channels under the News 12 Networks, Cheddar, and i24NEWS names. It also provides broadband communications and video services under the Optimum and Suddenlink brands. The company was incorporated in 2015 and is headquartered in Long Island City, New York
HIGH RISK!!
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0,82-11,56%
all time low
Dec 27, 2023 1.0900 0.9201 0.8120 0.8200 0.8200 435,687
Dec 26, 2023 1.0900 1.1200 0.9000 0.9270 0.9270 2,768,800
Dec 22, 2023 1.1800 1.1800 1.0700 1.1400 1.1400 623,400
Dec 21, 2023 1.1600 1.2150 1.0800 1.2000 1.2000 606,100
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,133,200
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Golden Heaven Group Holdings Ltd., an offshore holding company, engages in the development, construction, management, and operation of urban amusement parks, water parks, amusement projects, and amusement facilities in China. It operates six amusement parks, water parks, and complementary recreational facilities. The company was incorporated in 2020 and is headquartered in Nanping, the People's Republic of China.
https://www.jsyoule.com/
Total Cash (mrq) 28.26M
Total Debt (mrq) 6.8M
Float 1.69M
Shares Short (Nov 29, 2023) 395.64k
Nova LifeStyle, Inc. (NVFY) 1.6100+0.0100 (+0.62%)
52 Week Range 1.6000 - 6.8500
Shares Outstanding 1.63M
Implied Shares Outstanding 1.74M
Float 937.88k
Book Value Per Share (mrq) 2.54
Nova LifeStyle, Inc., through its subsidiaries, designs, manufactures, markets, and sells residential and commercial furniture for middle and upper middle-income consumers worldwide. The company offers upholstered, wood, and metal-based furniture pieces for the living, dining, and bedrooms, as well as home offices. Its products include sofas, chairs, dining tables, beds, entertainment consoles, cabinets, and cupboards. The company also provides physiotherapeutic jade mats for use in therapy clinic, hospitality, and real estate projects. It distributes its products under the Nova LifeStyle, Diamond Sofa, and Nova Living brand directly, as well as through internet sales and online marketing campaigns, and participation in exhibitions and trade shows primarily to furniture distributors and retailers. The company was formerly known as Stevens Resources, Inc. Nova LifeStyle, Inc. was founded in 2003 and is headquartered in Commerce, California.
https://novalifestyle.com/
Nova LifeStyle, Inc. (NVFY) 1.6100+0.0100 (+0.62%)
52 Week Range 1.6000 - 6.8500
Shares Outstanding 1.63M
Implied Shares Outstanding 1.74M
Float 937.88k
Book Value Per Share (mrq) 2.54
Nova LifeStyle, Inc., through its subsidiaries, designs, manufactures, markets, and sells residential and commercial furniture for middle and upper middle-income consumers worldwide. The company offers upholstered, wood, and metal-based furniture pieces for the living, dining, and bedrooms, as well as home offices. Its products include sofas, chairs, dining tables, beds, entertainment consoles, cabinets, and cupboards. The company also provides physiotherapeutic jade mats for use in therapy clinic, hospitality, and real estate projects. It distributes its products under the Nova LifeStyle, Diamond Sofa, and Nova Living brand directly, as well as through internet sales and online marketing campaigns, and participation in exhibitions and trade shows primarily to furniture distributors and retailers. The company was formerly known as Stevens Resources, Inc. Nova LifeStyle, Inc. was founded in 2003 and is headquartered in Commerce, California.
https://novalifestyle.com/
HIGH RISK!!
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.95 – 16.67%
all time low
Dec 26, 2023 1.0900 1.1200 0.9300 0.9600 0.9600 887,068
Dec 22, 2023 1.1800 1.1800 1.0700 1.1400 1.1400 623,400
Dec 21, 2023 1.1600 1.2150 1.0800 1.2000 1.2000 606,100
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,133,200
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Golden Heaven Group Holdings Ltd., an offshore holding company, engages in the development, construction, management, and operation of urban amusement parks, water parks, amusement projects, and amusement facilities in China. It operates six amusement parks, water parks, and complementary recreational facilities. The company was incorporated in 2020 and is headquartered in Nanping, the People's Republic of China.
https://www.jsyoule.com/
Total Cash (mrq) 28.26M
Total Debt (mrq) 6.8M
Float 1.69M
Shares Short (Nov 29, 2023) 395.64k
HIGH RISK!!
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 0.95 – 16.67%
all time low
Dec 26, 2023 1.0900 1.1200 0.9300 0.9600 0.9600 887,068
Dec 22, 2023 1.1800 1.1800 1.0700 1.1400 1.1400 623,400
Dec 21, 2023 1.1600 1.2150 1.0800 1.2000 1.2000 606,100
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,133,200
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Golden Heaven Group Holdings Ltd., an offshore holding company, engages in the development, construction, management, and operation of urban amusement parks, water parks, amusement projects, and amusement facilities in China. It operates six amusement parks, water parks, and complementary recreational facilities. The company was incorporated in 2020 and is headquartered in Nanping, the People's Republic of China.
https://www.jsyoule.com/
Total Cash (mrq) 28.26M
Total Debt (mrq) 6.8M
Float 1.69M
Shares Short (Nov 29, 2023) 395.64k
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 1.14
Time for a strong rebound?
Dec 21, 2023 1.1600 1.2000 1.0800 1.1400 1.1400 406,061
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,108,300
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Shares Outstanding 51.75M
Float 1.69M
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company’s website at https://ir.jsyoule.com/.
GOLDEN HEAVEN GROUP HOLDINGS LTD (GDHG) : 1.14
Time for a strong rebound?
Dec 21, 2023 1.1600 1.2000 1.0800 1.1400 1.1400 406,061
Dec 20, 2023 1.2500 1.3700 1.1500 1.1500 1.1500 1,108,300
Dec 19, 2023 1.2600 1.4900 1.2500 1.3200 1.3200 2,133,700
Dec 18, 2023 1.2400 1.3000 1.2300 1.2600 1.2600 1,542,000
Dec 15, 2023 1.3100 1.3700 1.2000 1.2900 1.2900 1,020,600
Dec 14, 2023 1.3100 1.4400 1.2600 1.3600 1.3600 1,044,000
Dec 13, 2023 1.4400 1.5500 1.2600 1.3600 1.3600 1,949,100
Dec 12, 2023 1.3200 1.5200 1.2200 1.4700 1.4700 2,475,800
Dec 11, 2023 1.1700 1.4200 1.0500 1.3100 1.3100 3,380,700
Dec 08, 2023 1.8200 1.8200 1.3300 1.3600 1.3600 7,763,600
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Shares Outstanding 51.75M
Float 1.69M
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company’s website at https://ir.jsyoule.com/.
U.S. Energy Corp. (USEG) 1.0500+0.0836 (+8.66%)
Shares Outstanding 25.51M
Implied Shares Outstanding 25.51M
Float 2.91M
Book Value Per Share (mrq) 2.59
U.S. Energy Corp. Declares Quarterly Cash Dividend
U.S. Energy Corp. (NASDAQCM: USEG announced that its Board of Directors has declared a cash dividend on the Company's common stock in the amount of $0.0225 per share.
time for a strong rebound:
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.1493 86,797,700
Aug 31, 2020 5.6100 18.5700 4.1300 5.0000 4.7693 17,575,900
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
U.S. Energy Corp. (USEG) 1.0500+0.0836 (+8.66%)
Shares Outstanding 25.51M
Implied Shares Outstanding 25.51M
Float 2.91M
Book Value Per Share (mrq) 2.59
U.S. Energy Corp. Declares Quarterly Cash Dividend
U.S. Energy Corp. (NASDAQCM: USEG announced that its Board of Directors has declared a cash dividend on the Company's common stock in the amount of $0.0225 per share.
time for a strong rebound:
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.1493 86,797,700
Aug 31, 2020 5.6100 18.5700 4.1300 5.0000 4.7693 17,575,900
ABOUT U.S. ENERGY CORP.
We are a growth company focused on consolidating high-quality producing assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program. We are committed to ESG stewardship and being a leader in reducing our carbon footprint in the areas in which we operate. More information about U.S. Energy Corp. can be found at www.usnrg.com.
QUINCE THERAPEUTICS INC QNCX 1,23 + 4,24%
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
We see more and more big shareholders, I think we will see 1.50 – 1.75 this week.
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission
https://quincetx.com/pipeline/
time for a strong rebound
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
QUINCE THERAPEUTICS INC QNCX 1,23 + 4,24%
GENEXTRA S.P.A. REPORTS 5.89% PASSIVE STAKE IN QUINCE THERAPEUTICS
Total Cash (mrq) 83.22M
Total Cash Per Share (mrq) 1.94
Total Debt (mrq) 61k
Book Value Per Share (mrq) 2.29
Shares Outstanding 42.87M
Float 31.07M
Shares Short (prior month Oct 30, 2023) 4 2.16M
We see more and more big shareholders, I think we will see 1.50 – 1.75 this week.
Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission
https://quincetx.com/pipeline/
time for a strong rebound
Dec 01, 2023 0.9100 1.0500 0.9100 1.0300 1.0300 1,362,700
Oct 31, 2023 0.9500 1.0000 0.8400 0.8900 0.8900 1,624,600
Sep 30, 2023 1.0770 1.2100 0.9300 0.9710 0.9710 1,406,800
Aug 31, 2023 1.3400 1.3600 1.0600 1.1200 1.1200 2,505,300
Jul 31, 2023 1.2100 1.3400 1.1700 1.3100 1.3100 3,672,400
Jun 30, 2023 1.4900 1.7000 1.0800 1.2000 1.2000 13,124,000
May 31, 2023 1.4900 1.6600 1.3500 1.5050 1.5050 1,769,200
Apr 30, 2023 1.5300 1.7400 1.3800 1.5000 1.5000 2,458,500
Mar 31, 2023 1.6100 1.9300 1.4300 1.5300 1.5300 6,290,800
Mar 01, 2023 0.9300 1.5800 0.7900 1.5600 1.5600 62,561,600
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
Yessss
FuelCell Energy, Inc. (FCEL) 1.5400-0.0200 (-1.2821%)
Pre-Market: 1.87 + 0.33 (+21.43%)
ExxonMobil to Build CCS Pilot Plant with FuelCell Energy Using Carbonate Fuel Cell Technology
• First time for carbonate fuel cell technology to be piloted for carbon capture in an industrial environment
• Captured CO2 will be transported and stored via the Porthos project for permanent storage under the North Sea
• If successful, the technology would be commercialized to reduce emissions at ExxonMobil locations and other industrial sites to help customers reduce their emissions
ROTTERDAM, Netherlands and DANBURY, Conn., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ExxonMobil’s affiliate Esso Nederland BV plans to build a pilot plant at its Rotterdam Manufacturing Complex to test a breakthrough technology that could significantly reduce CO2 emissions from key industries. The pilot plant aims to obtain data on performance and operability of the carbonate fuel cell (CFC) technology, jointly developed with FuelCell Energy. Additionally, the pilot aims to address potential technical issues that may occur in a commercial environment and better understand the costs of installing and operating a CFC plant for carbon capture.
Esso’s Rotterdam integrated manufacturing site will be the first place in the world to pilot this technology. Pending a successful demonstration, ExxonMobil could deploy this technology at its manufacturing sites around the world.
Carbonate fuel cells have a unique ability to capture CO2 emissions from industrial sources before they are released into the atmosphere, while also making valuable co-products. This feature increases the overall efficiency of the capture process and provides additional value streams that reduce the cost of carbon capture and storage.
CFC technology is also modular, potentially enabling carbon capture across a wide range of deployment scales. When the CFC technology is technically ready for broadscale implementation, it could potentially offer economical decarbonization solutions for customers from a wide range of industries and serve the broader social goal of working towards a net-zero future.
“The unique advantage of this technology is that it not only captures CO2 but also produces low carbon power, heat, and hydrogen as co-products,” said Geoff Richardson, SVP of Commercial and Business Development for ExxonMobil Low Carbon Solutions. “We are excited for the opportunity to pilot this innovation at our own Rotterdam facility.”
"FuelCell Energy and ExxonMobil believe that capturing carbon at the source is an efficient way to decarbonize heavy industry. This technology can capture carbon and produce electricity simultaneously, making it a game-changer in the industry," said FuelCell Energy President and Chief Executive Officer Jason Few.
The pilot project is co-funded by the European Union under the Emissions Trading System Innovation Fund and by the Netherlands Enterprise Agency by means of a Demonstration Energy and Climate Innovation (DEI+) grant.
About ExxonMobil
ExxonMobil, one of the largest publicly traded international energy and petrochemical companies, creates solutions that improve quality of life and meet society’s evolving needs.
The corporation’s primary businesses - Upstream, Product Solutions and Low Carbon Solutions – provide products that enable modern life, including energy, chemicals, lubricants, and lower emissions technologies. ExxonMobil holds an industry-leading portfolio of resources, and is one of the largest integrated fuels, lubricants, and chemical companies in the world. ExxonMobil also owns and operates the largest CO2 pipeline network in the United States. In 2021, ExxonMobil announced Scope 1 and 2 greenhouse gas emission-reduction plans for 2030 for operated assets, compared to 2016 levels. The plans are to achieve a 20-30% reduction in corporate-wide greenhouse gas intensity; a 40-50% reduction in greenhouse gas intensity of upstream operations; a 70-80% reduction in corporate-wide methane intensity; and a 60-70% reduction in corporate-wide flaring intensity.
With advancements in technology and the support of clear and consistent government policies, ExxonMobil aims to achieve net-zero Scope 1 and 2 greenhouse gas emissions from its operated assets by 2050. To learn more, visit exxonmobil.com and ExxonMobil’s Advancing Climate Solutions.
Follow us on LinkedIn, I and X.